213 results about "Cancer prognosis" patented technology

The invention relates to a method for determining a prognosis for a cancer by quantifying vitamin receptor expression on the cancer cells. The method comprises the steps of quantifying vitamin receptor expression on the cancer cells, and determining a prognosis for the cancer. The invention also relates to methods and kits for determining the presence of vitamin receptors on cancer cells to select patients that should be treated with a therapy that utilizes vitamin receptor targeting and to develop a treatment regimen for such patients. The invention further relates to kits for performing the methods.

The present invention provides multifunctional nanoplatforms for assessing the activity of a protease in vivo or in vitro, along with methods of imaging and detecting the presence of cancerous or precancerous tissues, and the therapeutic treatment thereof, including monitoring of treatment. The diagnostic nanoplatforms comprise nanoparticles and are linked to each other or other particles via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected using various sensors, and the diagnostic results can be correlated with cancer prognosis. Individual unlinked nanoplatforms are also adaptable for therapeutic hyperthermia treatment of the cancerous tissue.

The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and/or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor/cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development.

Disclosed herein are polynucleotide adaptors and methods of use thereof for identifying and analyzing nucleic acids, including cell-free nucleic acids from a patient sample. Also disclosed herein are methods of using the adaptors to detect, diagnose, or determine prognosis of cancers.

The present invention relates to a gene and/or protein expression based method of predicting response to platinum based chemotherapy for lung cancer patients, as well as a method of predicting prognosis of survival based on protein expression and type of lung cancer. The invention also provides novel targets for screening candidate anti-cancer agents.

The invention discloses tumor marker colloidal gold immunochromatographic assay quantitative detection test paper and a method for preparing the same. The test paper comprises a sample pad, a gold-labeled antibody conjugate film, a nitrocellulose membrane, a water absorbing cushion and a reaction support, wherein the nitrocellulose membrane of which the end close to the sample pad is used as a starting end and the end close to the water absorbing cushion is used as a tail end is enveloped by five antibody strips in turn, namely T1, T2, T3 and T4 detection strips of mouse anti-human tumor marker monoclonal antibody I and a C quality control strip of goat anti-mouse IgG respectively; and the gold-labeled antibody conjugate film is a film coated with a colloidal gold-labeled mouse anti-human tumor marker monoclonal antibody II. The test paper and the method realize rapid and accurate quantitative detection of the tumor marker and thus meet the requirement of rapid detection of cancer surveying and screening, family cancer prognosis monitoring and the like.

Gene-Based Algorithmic Cancer Prognosis relates to methods and systems for prognosis determination in tumor samples. The methods and systems measure gene expression in a tumor sample and applying a gene-expression grade index (GGI) or a relapse score (RS) to yield a number c risk score.

The present invention relates to a marker for predicting a gastric cancer prognosis, a composition and a kit for predicting gastric cancer prognosis comprising an agent for measuring the expression level thereof, and a method for predicting gastric cancer prognosis using the marker. According to the present invention, gastric cancer prognosis may be predicted promptly and accurately, and an appropriate treatment plan can be determined based on the predicted prognosis, which has an advantage of contributing to significant reduction of death caused by gastric cancer. Particularly, according to the present invention, the survival rate can be remarkably increased by using the treatment method for a stage III gastric cancer patient to a patient who has been predicted to have a negative prognosis among stage Ib/II gastric cancer patients.

The invention provides a method and a composition used for evaluating patients with breast cancer, particularly the prognosis of the patients with the breast cancer at an early stage. The method of the invention comprises the detection of at least one of body samples, particularly the expression of at least two biological markers, wherein, the over-expression of the biological markers or the combination of the biological markers indicates the prognosis of the breast cancer. The body samples in a plurality of implementation proposals are the mammary tissue samples, particularly the primary breast tumor samples. The biological markers of the invention are proteins and/or genes, and the over-expression indicates the good or poor cancer prognosis. The concerned biological markers include the proteins and genes which participate in cell cycle regulation, DNA replication, transcription, signal transduction, cell proliferation, cell invasion, protein hydrolysis or transfer. The biological marker-specific antibody is used on the protein level or the nucleic acid hybridization technology is used on the nucleic acid level for detecting the over-expression of the concerned biological markers in certain aspects of the invention.

The invention discloses a multiple PCR primer group for detecting a gene related to colorectal cancer administration. The primer group comprises an upstream primer group and a downstream primer group, wherein the 5' end sequence of the upstream is complementary to partial sequence of a to-be-detected primer, and the 3' end of the upstream primer is a specific sequence combined to a target zone; the 5' end sequence of the downstream primer is complementary with partial sequence of the to-be-detected primer, and the 3' end of the downstream primer is a specific sequence combined to the target zone, and the sequence of the middle position of the downstream primer is a molecule tag sequence. The invention further discloses a kit containing the multiple PCR primer group and a method for detecting the gene related to colorectal cancer administration, which can be used for simultaneously detecting exon regions of 8 genes related to target medicines for treating colorectal cancer and mutation of 23 polymorphic sites related to chemotherapeutic drugs, can be directly used for assisting clinical colorectal cancer administration, and can be used in cancer early diagnosis, auxiliary diagnosis and screening or cancer prognosis monitoring.

The present invention provides a system for accurately predicting the prognosis of gastric cancer patients. The system is based on the Nomogram prognostic prediction model constructed by the present invention. Compared with the traditional TNM staging system, the system has high accuracy, individualized prediction, and conforms to Prognostic features of gastric cancer with Chinese characteristics.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.

The invention provides a separation method of circulating tumor cells (CTCs). The method comprises the following steps: enriching mononuclear cells (PBMC) from a blood sample through density gradient centrifugation; carrying out invasion experiments on the enriched PBMCs, and collecting invasive cells; and dyeing and sorting the collected cells. The invention also provides a detection method of the CTCs. The methods are not influenced by the heteroplasmy of the CTCs, the separated CTCs are tumor cells with invasion ability and are more than CTCs with invasion ability, obtained through an immunomagnetic bead screening method, the CTCs can be used in tumor transfer researches in the laboratory, and CTC detection can be used as the biomarker liquid biopsy of the cancer prognosis and treatment effect.